These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22469863)

  • 21. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia.
    Gertig DM; Brotherton JM; Saville M
    Sex Health; 2011 Jun; 8(2):171-8. PubMed ID: 21592430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M
    Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.
    Weinberg A; Huang S; Moscicki AB; Saah A; Levin MJ;
    AIDS; 2018 Apr; 32(7):851-860. PubMed ID: 29424778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adolescents' awareness of HPV infections and attitudes towards HPV vaccination 3 years following the introduction of the HPV vaccine in Hungary.
    Marek E; Dergez T; Rebek-Nagy G; Kricskovics A; Kovacs K; Bozsa S; Kiss I; Ember I; Gocze P
    Vaccine; 2011 Nov; 29(47):8591-8. PubMed ID: 21939711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
    J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age considerations when vaccinating against HPV.
    Wright TC; Huh WK; Monk BJ; Smith JS; Ault K; Herzog TJ
    Gynecol Oncol; 2008 May; 109(2 Suppl):S40-7. PubMed ID: 18482558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events.
    Callréus T; Svanström H; Nielsen NM; Poulsen S; Valentiner-Branth P; Hviid A
    Vaccine; 2009 May; 27(22):2954-8. PubMed ID: 19428906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-licensure monitoring of HPV vaccine in the United States.
    Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
    Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human papilloma vaccination to adolescents.
    Levavi H
    Pediatr Endocrinol Rev; 2010 Sep; 8(1):2-5. PubMed ID: 21037538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical implementation of HPV vaccines in clinical practice.
    Kimmel SR
    J Fam Pract; 2006 Nov; Suppl():18-22. PubMed ID: 17366754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus vaccine acceptability among young adult men.
    Gerend MA; Barley J
    Sex Transm Dis; 2009 Jan; 36(1):58-62. PubMed ID: 18830138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
    Stanley M; Gissmann L; Nardelli-Haefliger D
    Vaccine; 2008 Aug; 26 Suppl 10():K62-7. PubMed ID: 18847558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The attitudes of Australian gynaecologists to HPV vaccination: an ASCCP survey.
    Tan J; Farrell L; Allen DG
    Aust N Z J Obstet Gynaecol; 2010 Oct; 50(5):472-7. PubMed ID: 21039383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
    Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
    Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
    Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.